CEO Christopher Viehbacher has said consistently since he took the helm of Biogen in 2022 that the company will grow through both internal and external innovation, with an overarching goal of diversifying beyond neurology further into rare diseases and immunology. The hiring of Jane Grogan as head of research a year later reinforced that strategy and the new member of the leadership team told Scrip that she spent 2024 reorganizing her group with those overarching goals in mind.
How Research Head Jane Grogan Is Reinforcing Biogen’s Internal And External R&D Focus
Immunology Interests Fall Into Three ‘Buckets’
CEO Christopher Viehbacher has said repeatedly that Biogen will build its pipeline internally and through deals, and Grogan reshuffled the research organization with that in mind.
More from Strategy
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.